JP2009538318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538318A5 JP2009538318A5 JP2009512164A JP2009512164A JP2009538318A5 JP 2009538318 A5 JP2009538318 A5 JP 2009538318A5 JP 2009512164 A JP2009512164 A JP 2009512164A JP 2009512164 A JP2009512164 A JP 2009512164A JP 2009538318 A5 JP2009538318 A5 JP 2009538318A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- pharmaceutically acceptable
- dione
- amino
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 32
- 239000011780 sodium chloride Substances 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 12
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 12
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 12
- 229960001330 hydroxycarbamide Drugs 0.000 claims 12
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 claims 12
- 229940027318 hydroxyurea Drugs 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 12
- 229960000604 valproic acid Drugs 0.000 claims 12
- UVSMNLNDYGZFPF-UHFFFAOYSA-N Pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 11
- 206010061590 Blood disease Diseases 0.000 claims 6
- 201000002138 hematopoietic system disease Diseases 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 4
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 3
- 102100016492 CD34 Human genes 0.000 claims 3
- 108060001251 CD34 Proteins 0.000 claims 3
- 208000005209 Hematologic Disease Diseases 0.000 claims 3
- 210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims 3
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 3
- 201000002393 blood protein disease Diseases 0.000 claims 3
- -1 2,6-dioxo (3-piperidyl) Chemical group 0.000 claims 2
- 210000001185 Bone Marrow Anatomy 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010028576 Myeloproliferative disease Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000005510 acute lymphocytic leukemia Diseases 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 108010044495 Fetal Hemoglobin Proteins 0.000 claims 1
- 208000001284 Hemoglobinopathy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000007056 Sickle Cell Anemia Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003923 hemoglobinopathy Diseases 0.000 claims 1
- 230000002519 immonomodulatory Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80860206P | 2006-05-26 | 2006-05-26 | |
| PCT/US2007/012495 WO2007139939A2 (en) | 2006-05-26 | 2007-05-24 | Methods and compositions using immunomodulatory compounds in combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009538318A JP2009538318A (ja) | 2009-11-05 |
| JP2009538318A5 true JP2009538318A5 (es) | 2010-07-29 |
Family
ID=38606531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009512164A Pending JP2009538318A (ja) | 2006-05-26 | 2007-05-24 | 併用療法において免疫調節化合物を用いる方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP2023912A2 (es) |
| JP (1) | JP2009538318A (es) |
| KR (1) | KR20090014393A (es) |
| CN (1) | CN101495111A (es) |
| AU (1) | AU2007267928A1 (es) |
| CA (1) | CA2652888A1 (es) |
| IL (1) | IL195412A0 (es) |
| MX (1) | MX2008014912A (es) |
| RU (1) | RU2426542C2 (es) |
| WO (1) | WO2007139939A2 (es) |
| ZA (1) | ZA200809956B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009097120A1 (en) * | 2008-01-29 | 2009-08-06 | Celgene Corporation | Methods using immunomodulatory compounds for modulating level of cd59 |
| CA2868302A1 (en) * | 2012-03-23 | 2013-09-26 | Dennis M. Brown | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo |
| ES2754199T3 (es) * | 2013-08-22 | 2020-04-16 | Vanda Pharmaceuticals Inc | Tricostatina A para el tratamiento del mieloma múltiple |
| CN105579101A (zh) | 2013-08-22 | 2016-05-11 | 万达制药公司 | 癌症的治疗 |
| JP2017511132A (ja) * | 2014-03-26 | 2017-04-20 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法 |
| WO2015175916A1 (en) * | 2014-05-16 | 2015-11-19 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6 dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment of cancers |
| WO2023034504A1 (en) * | 2021-09-01 | 2023-03-09 | Flagship Pioneering Innovations Vi, Llc | Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CN103393681B (zh) * | 2002-05-17 | 2017-04-12 | 细胞基因公司 | 用于治疗和控制多发性骨髓瘤的方法及组合物 |
| CN101108185A (zh) * | 2002-10-24 | 2008-01-23 | 细胞基因公司 | 用于治疗、改变和控制疼痛的包含免疫调节化合物的组合物 |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| CN101966183A (zh) * | 2003-12-02 | 2011-02-09 | 细胞基因公司 | 用于治疗和控制血红蛋白病和贫血病的方法和组合物 |
| US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
-
2007
- 2007-05-24 MX MX2008014912A patent/MX2008014912A/es not_active Application Discontinuation
- 2007-05-24 JP JP2009512164A patent/JP2009538318A/ja active Pending
- 2007-05-24 AU AU2007267928A patent/AU2007267928A1/en not_active Abandoned
- 2007-05-24 CN CNA2007800277224A patent/CN101495111A/zh active Pending
- 2007-05-24 RU RU2008151713/15A patent/RU2426542C2/ru not_active IP Right Cessation
- 2007-05-24 ZA ZA200809956A patent/ZA200809956B/xx unknown
- 2007-05-24 WO PCT/US2007/012495 patent/WO2007139939A2/en active Application Filing
- 2007-05-24 CA CA002652888A patent/CA2652888A1/en not_active Abandoned
- 2007-05-24 EP EP07795353A patent/EP2023912A2/en not_active Withdrawn
- 2007-05-24 KR KR1020087031357A patent/KR20090014393A/ko not_active Application Discontinuation
-
2008
- 2008-11-20 IL IL195412A patent/IL195412A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538318A5 (es) | ||
| Pusic et al. | Update on clinical experience with AMD3100, an SDF-1/CXCL12–CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells | |
| KR100711181B1 (ko) | 골수형성이상 증후군의 치료 및 관리를 위한 면역조절화합물의 사용 방법 및 이를 포함하는 조성물 | |
| AU2011253161B2 (en) | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine | |
| JP4865027B2 (ja) | 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 | |
| KR101483802B1 (ko) | 외투층 세포 림프종의 치료에 있어서 3-(4-아미노-1-옥소-1,3-디히드로-이소인돌-2-일)-피페리딘-2,6-디온의 용도 | |
| US20050143420A1 (en) | Methods and compositions for the treatment and management of hemoglobinopathy and anemia | |
| WO2001062234A2 (en) | Dosing regimen | |
| CA2672000A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma | |
| JP2013231086A (ja) | 化学療法の強化方法 | |
| WO2001064246A2 (en) | Farnesyl protein transferase inhibitor combinations with an her2 antibody | |
| KR20140008282A (ko) | 혈액암의 치료 | |
| HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
| US20080051431A1 (en) | Methods and compositions using immunomodulatory compounds in combination therapy | |
| JP2006503866A (ja) | 癌を処置するための相乗的な方法および組成物 | |
| KR101575706B1 (ko) | 암 치료용 선택적인 ｅｐ４ 수용체 길항제 | |
| EP1261348A2 (en) | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents | |
| WO2017042944A1 (ja) | フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法 | |
| RU2008151713A (ru) | Способы и композиции с применением иммуномодулирующих соединений при комбинированном лечении | |
| US20030181473A1 (en) | Farnesyl protein transferase inhibitor combinations with taxane compounds | |
| EP1261343A2 (en) | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives | |
| Annageldiyev et al. | The PI3K/AKT pathway inhibitor ISC-4 induces apoptosis and inhibits growth of leukemia in preclinical models of acute myeloid leukemia | |
| WO2001064218A2 (en) | Farnesyl protein transferase inhibitor combinations | |
| Economides et al. | Novel therapies in myeloproliferative neoplasms (MPN): beyond JAK inhibitors | |
| JP2018516936A5 (es) |